Tgf Beta Signaling Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes.
The Transforming Growth Factor-beta (TGF-β) signaling pathway is a highly conserved cellular communication system that plays dual roles in the nervous system—promoting neuronal survival under normal conditions while contributing to disease progression when dysregulated. TGF-β signaling regulates neuroinflammation, neurogenesis, synaptic plasticity, and oligodendrocyte function, making it a critical pathway in neurodegenerative disease pathogenesis[1][2]. [1]
| Component | Symbol | Function | [2]
|-----------|--------|----------| [3]
| TGF-β1 | TGFB1 | Pro-inflammatory cytokine, key in neuroinflammation | [4]
| TGF-β2 | TGFB2 | Oligodendrocyte differentiation, myelination | [5]
| TGF-β3 | TGFB3 | Neuronal survival, synaptic plasticity | [6]
| TGF-β Receptor I | TGFBR1 | Serine/threonine kinase, primary signal transducer | [7]
| TGF-β Receptor II | TGFBR2 | Constitutively active kinase, ligand binding | [8]
| SMAD2 | SMAD2 | R-SMAD, TGF-β canonical pathway | [9]
| SMAD3 | SMAD3 | R-SMAD, transcription co-activator | [10]
| SMAD4 | SMAD4 | Co-SMAD, forms complexes with R-SMADs | [11]
| SMAD6/7 | SMAD6/7 | I-SMAD, inhibitory SMADs | [12]
| SARA | SMAD anchor for receptor activation | Facilitates SMAD2/3 recruitment | [13]
The TGF-β superfamily bifurcates into two major subpathways:
This distinction is therapeutically important as BMP signaling promotes neurogenesis while TGF-β signaling can be pro-inflammatory.
TGF-β signaling exhibits complex, stage-dependent effects in AD:
Key publications:
TGF-β signaling intersects with multiple PD-relevant pathways:
Key publications:
TGF-β dysregulation contributes to motor neuron pathology:
Key publications:
Beyond canonical SMAD signaling, TGF-β activates:
| Agent | Mechanism | Status | Disease |
|-------|--------|---------|
| Rec---|--------ombinant TGF-β1 | Direct neurotrophic factor | Preclinical | PD, HD |
| BMP-7 (Osteogenic Protein-1) | BMP pathway activation | Phase II (withdrawn) | PD |
| TGF-β gene therapy | AAV-mediated delivery | Preclinical | AD |
| Agent | Mechanism | Status | Disease |
|---|---|---|---|
| SB-431542 | TβRI kinase inhibitor | Preclinical | ALS |
| SD-208 | TβRI kinase inhibitor | Preclinical | ALS, PD |
| LY2109761 | TβRI/II dual inhibitor | Preclinical | ALS |
| Fresolimumab | Anti-TGF-β1 antibody | Phase I/II | IPF, oncology |
| Biomarker | Source | Disease | Utility |
|---|---|---|---|
| TGF-β1 | CSF, serum | AD, PD, ALS | Disease progression |
| p-SMAD2/3 | CSF | AD | Diagnostic |
| SMAD7 | Blood | ALS | Progression marker |
| TGFBR2 expression | Blood cells | PD | Susceptibility |
-拮抗关系 in neurogenesis
The TGF-β signaling pathway represents a critical nexus in neurodegenerative disease pathogenesis, with dual roles in neuronal survival and neuroinflammation. While TGF-β agonism shows promise for promoting neuronal survival and Aβ clearance, chronic elevation contributes to pathology. Therapeutic modulation requires careful targeting—ideally restoring physiological signaling rather than complete blockade. The growing understanding of SMAD and non-SMAD pathway interactions, combined with biomarker development, positions TGF-β signaling as an increasingly tractable therapeutic target.
The study of Tgf Beta Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 36%
This section summarizes key publications from the last two years that advance our understanding of this mechanism.
Tesseur I, Wyss-Coray T (2006) A role for TGF-β in Alzheimer's disease? Nat Med. 2006. ↩︎
Wyss-Coray T, et al. (2001) TGF-β1 improves Aβ clearance. 2001. ↩︎
Ueberham U, Ueberham E (2020) TGF-β in Alzheimer's disease. J Neural Transm. 2020. ↩︎
Tesseur I, et al. (2006) Deficiency in neuronal TGF-beta signaling. 2006. ↩︎
Wyss-Coray T, et al. (2000) TGF-β1 reduces amyloid plaques. 2000. ↩︎
Krieglstein K, et al. (1995) TGF-β protects dopaminergic neurons. 1995. ↩︎
Sortwell CE, et al. (2000) TGF-β1 protects dopaminergic neurons. 2000. ↩︎
Chao CC, et al. (2009) TGF-β in Parkinson's disease. 2009. ↩︎
Endo R, et al. (2015) TGF-β in ALS. 2015. ↩︎
Phatnani HP, et al. (2013) ALS SMART. 2013. ↩︎
Van Hoecke A, et al. (2012) EPHA4 in ALS. 2012. ↩︎
Blurton-Jones M, et al. (2009) Neural stem cells and TGF-β. 2009. ↩︎
Yousef H, et al. (2019) TGF-β and aging. 2019. ↩︎